A specific postmarketing study of clavulanic acid/amoxicillin (1:14) dry syrup for pediatric in pediatric patients with infection

Japanese Journal of Chemotherapy

Volumn 57, Issue 5, 2009, Pages 438-452

  Ouchi, Kazunobu ^a   Iwata, Satoshi ^b   Okano, Hideyuki ^c   Abe, Hiroharu ^c  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

^c Development and Medical Affairs Division   (Japan)

Author keywords

Child; Clavulanic acid amoxicillin; Efficacy; Postmarketing surveillance; Safety

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID;

ARTICLE; BRONCHITIS; CHILD; CYSTITIS; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; LARYNGITIS; LYMPHADENITIS; LYMPHANGITIS; MAJOR CLINICAL STUDY; MALE; MORAXELLA CATARRHALIS; PHARYNGITIS; PRESCHOOL CHILD; RESPIRATORY TRACT INFECTION; SCHOOL CHILD; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; SYRUP; TONSILLITIS; URINARY TRACT INFECTION; VOMITING;

EID: 71049191478     PISSN: 13407007     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Jpn J Antibiot 2007; 60: 221-241
2. Bottenfield G W, Burch D J, Hedrick J A, Schaten R, Rowinski C A, Davies J T: Safety and tolerability of a new formulation (90 mg/kg/day divided every 12 h) of amoxicillin/clavulanate (Augmentin) in the empiric treatment of pediatric acute otitis media caused by drug-resistant Streptococcus pneumoniae. Pediatr Infect Dis J 1998; 17: 963-968 (Pubitemid 28506435)
3. Clinical and Laboratory Standards Institute: Performance standards for antimicrobial susceptibility testing; Seventeenth informational supplement (M100-S17, 2007)
4. Jpn J Antibiot 2009; 62: 90-102